Using Risk Thanks to Predictions to Find CKD Risk and Improve Testing
Official title: The Use of Risk Prediction to Identify Patients at Risk for Chronic Kidney Disease (Short Name: RISK [Risk InterventionS for Chronic Kidney Disease])
Run by Kaiser Permanente · NCT07857200 · Data updated 2026-11-12
We’re testing whether targeted provider and patient communications can help people at high risk for chronic kidney disease get the recommended kidney tests.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 1500 (estimated) |
| Sponsor | Kaiser Permanente Academic / other |
| Locations | 1 site (Portland, Oregon) |
| Status | Recruiting |
| Started | August 20, 2026 |
| Main results expected | August 20, 2027 |
| Study ends | December 31, 2027 |
| Registry record updated | October 5, 2026 |
| Trial ID | NCT07857200 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults 18-80 at high CKD risk identified by the Phase 1 CKD model, with at least 12 months of health plan coverage, who speak English or Spanish.
✕Probably not a fit
Patients not at high CKD risk or those with language barriers preventing intervention may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This pragmatic, cluster-randomized study embeds a risk-based outreach into routine care to see if it increases completion of CKD-related lab tests (eGFR and uACR) among adults identified as high risk. Up to 1,000 patients will be identified using a CKD risk model from Phase 1, and their primary care providers will be notified with testing recommendations. Providers will be randomized to receive letters alone or letters plus phone outreach, with an augmented usual care arm to compare effectiveness in real-world practice. The trial takes place within Kaiser Permanente Northwest, leveraging existing clinical workflows and communications.
Why it matters
Potential benefit: If successful, this approach could lead to higher rates of CKD screening and earlier detection in high-risk patients.
How similar studies have gone: Previous studies using targeted provider and patient communications have shown promise in improving follow-up testing in chronic disease; this study applies a real-world, pragmatic approach to CKD.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * At high risk for CKD as determined by CKD model developed in Phase 1 * Age 18-80 as of date of data pull * At least 12 months of health plan coverage * Speaks English or Spanish * We will include both paneled and unpaneled patients Exclusion criteria: * On the research exclusion list between 1/1/2013 and date of the data pull * On hospice, or have conditions that indicate end of life (metastatic cancer, on dialysis, etc.) * Non-English / non-Spanish speaking (those who are excluded from the intervention arm solely due to language barriers will be reported to the IRB at continuing review). * Pregnant patients. * Patients who have a completed both the eGFR and uACR within the 12 months prior to the date of cohort identification.
Where it's running
-
Center for Health Research, Kaiser Permanente NW
Portland, Oregon, United States Recruiting
Study contacts
- Study coordinator: Amanda F Pretrik, PhD
- Email: Amanda.F.Petrik@kpchr.org
- Phone: 503-335-2400
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Walnuts and a Mediterranean-style diet to protect kidney and heart health
This study tests whether adding 30 g of raw walnuts daily to a Mediterranean-style diet helps kidney function and heart risk markers in adults with chronic kidney disease.
-
Dietary nitrate (beetroot juice) for high blood pressure and hypertensive kidney injury
This study will try beetroot juice (a source of dietary nitrate) to see if it lowers blood pressure and increases kidney blood flow in people with hypertension and early-to-moderate chronic kidney disease.
-
Cardio-renal outcomes with SGLT2 inhibitors in CKD patients with HFpEF
This project will try to see if people with stage 3–4 CKD and HFpEF who take SGLT2 inhibitors have better heart and kidney outcomes than similar patients who do not.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.